Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.57 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048283 | 0.93 | CTSK (0.61) | CTSKCTSSCTSL | |
| SCHEMBL4042634 | 0.91 | CTSK (0.67) | CTSKCTSSCTSL | |
| SCHEMBL4049225 | 0.91 | CTSK (0.58) | CTSKCTSSCTSL | |
| SCHEMBL4038525 | 0.90 | CTSK (0.59) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL4038247 | 0.90 | CTSK (0.59) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL4040078 | 0.89 | CTSK (0.58) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL4046571 | 0.89 | CTSK (0.60) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL4039951 | 0.89 | CTSK (0.57) | CTSKCTSSCTSLCTSBCDK4 | |
| SCHEMBL4043241 | 0.89 | CTSK (0.57) | CTSKCTSSCTSLCTSBITGB3 | |
| SCHEMBL4042677 | 0.89 | CTSK (0.57) | CTSKCTSSCTSLCTSBITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CTSL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.